Evidence map›Paper›PMID 41053875›Full record

ArticleStem cell research & therapy2025

Mesenchymal stromal cells attenuate primary sjogren's syndrome by modulating PD-1

Shiyi Zhang, Fanzhang Yin, Rui Chai, Tao Li, Yingying Gao, Xiaoxiang Chen, Genhong Yao, Xiaojun Tang, Xiaojuan Han, Betty P Tsao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shiyi Zhang *Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Fanzhang Yin *Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Rui ChaiDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.
Tao LiDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Yingying GaoThe Departments of Rheumatology, Nantong Key Laboratory of Innovative Research on Rheumatology and Immunology, Nantong First People's Hospital, Nantong Hospital of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Nantong, Jiangsu, China.
Xiaoxiang ChenThe Departments of Rheumatology, Nantong Key Laboratory of Innovative Research on Rheumatology and Immunology, Nantong First People's Hospital, Nantong Hospital of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Nantong, Jiangsu, China.
Genhong YaoDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Xiaojun TangDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Xiaojuan HanDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Betty P TsaoDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Linyu GengDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. genglinyu1987@163.com.
Lingyun SunDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. lingyunsun@nju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the role of PD-1

methodsWe measured the frequencies and numbers of T cell subsets, including Tph cells, follicular helper T (Tfh) cells, and Treg cells, as well as the levels of IL-21 in patients with pSS and healthy controls (HC). Additionally, we analyzed their correlations with the levels of serological indicators (IgG, C3, C4) and the score of the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). Immunofluorescence technique was employed to assess the infiltration of lymphocytes in labial gland tissues. Fluorescence-activated cell sorting (FACS) was used to detect the changes of Tph, Tfh, and Treg cell subsets 24 h pre- and post-mesenchymal stromal cells transplantation (MSCT). Meanwhile, proteomic analysis of peripheral blood samples was conducted to identify the key proteins associated with Tph cells, and these proteins were subsequently validated in vitro.

resultsPD-1

conclusionOur study established a link between increased Tph cell counts and increased Tph/Treg ratios with enhanced disease activity in pSS patients. MSC therapy, which reduces the number of Tph cells by inducing the expression of galectin-1, emerges as a promising therapeutic approach for pSS.

Indexed as

Galectin 1Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationProgrammed Cell Death 1 ReceptorSjogren's SyndromeT-Lymphocytes, Helper-InducerAdultFemaleHumansMaleMiddle AgedReceptors, CXCR5T-Lymphocytes, RegulatoryCXCR5 protein, humanGalectin 1PDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CXCR5Galectin-1IL-21Mesenchymal stromal (stem) cellPeripheral helper T cellPrimary sjögren's syndrome

Identifiers

PMID41053875
PMCPMC12502370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.